Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +35

Should You Buy Intuitive Surgical Stock Now Or Wait?

Earnings report Legal settlement AI-generated analysis

πŸ“ˆ Intuitive Surgical shares have gained 30.9% in three months, including a 9.4% jump on November 4, though they remain 18.7% below their January high.

πŸ’° The stock trades at 56.9 times trailing earnings, compared to 22.8x for the S&P 500, with management noting 84% of third-quarter revenue is recurring.

βš–οΈ Third-quarter net margin was 17.1%, down from 28.3% in the second quarter, due to a $450 million litigation settlement with U.S. customers.

πŸ“‰ Analysts expect Intuitive Surgical to grow revenue about 15% in the fourth quarter of 2026 to meet expectations of $3.3 billion.

πŸ”¬ Management narrowed da Vinci procedure growth guidance to 14-15% for 2026 after previously projecting 13.5-15.5%.

πŸ‡¨πŸ‡³ Lower prices in China and wider pricing actions on instruments are expected to lower revenue per procedure by 3-5% once fully implemented.

πŸ“… Intuitive Surgical is scheduled to report fourth-quarter 2026 results in January 2027, alongside updated long-term opportunity estimates.

πŸ“‰ The stock fell 12.2% following the July 2026 report and rose 19.1% after the October 2025 report, highlighting earnings-driven volatility.

πŸ›‘οΈ During the 2025 tariff shock, Intuitive Surgical declined 26.0%, outperforming the S&P 500's 19.0% decline in terms of downside protection relative to its own history.

Bullish Signals
  • The company maintains a high recurring revenue base, with management stating that 84% of third-quarter revenue was recurring.
  • Intuitive Surgical has demonstrated strong historical growth, with revenue increasing between 18.5% and 23.0% in each of the past four quarters.
  • The stock showed resilience during market stress, falling only 26.0% during the 2025 tariff shock compared to a broader market decline.
Risk Factors
  • Third-quarter net margin was significantly depressed at 17.1% due to a $450 million litigation settlement with U.S. customers.
  • Management expects lower prices in China and wider pricing actions on instruments will reduce da Vinci instrument and accessory revenue per procedure by about 3% to 5%.
  • Analysts anticipate a slowdown in growth, expecting only about 15% revenue growth in the fourth quarter of 2026 compared to higher single-digit or double-digit growth previously.
  • The stock remains 18.7% below its January high, suggesting recent gains may have already priced in much of the positive momentum.
Full Analysis
Intuitive Surgical (ISRG) shares have rallied 30.9% over the past three months, driven by a recent 9.4% jump despite the broader S&P 500 remaining flat. However, the stock remains 18.7% below its January high and trades at a premium valuation of 56.9 times trailing earnings, significantly higher than the S&P 500's multiple of 22.8x. Financial analysis indicates that much of this recent price appreciation has already been priced into the stock's earnings multiple, which rose from 48.0x at the end of September to current levels. The company reported a third-quarter operating margin of 32.3%, though net margins were impacted by a $450 million litigation settlement with U.S. customers, resulting in a net margin of 17.1% compared to 28.3% in the prior quarter. Analysts forecast Intuitive Surgical needs approximately 15% revenue growth in the fourth quarter of 2026 to meet expectations, projecting $3.3 billion against $2.87 billion a year earlier. Management has narrowed its guidance for da Vinci procedure growth to 14-15% for 2026 and anticipates lower prices in China will reduce revenue per procedure by 3-5% once fully implemented. The stock faces volatility ahead of the fourth-quarter 2026 earnings report expected in January 2027, where management plans to provide operating expense guidance. Historical data shows significant price swings following reports, with the stock falling 26% during a previous tariff shock, suggesting investors must weigh the risk of missing out on upside if results beat forecasts against the potential for downside if they miss.